TCT Receives Patent on Small Molecule for Treating Multiple Cancer Types
/EINPresswire.com/ SANTA ROSA, CA (2/14/12) --Targeted Cancer Therapeutics LLC (TCT) announced that its Nucleophosmin 1 (NPM1) inhibitor, NSC348884, received the U.S. Designation of Patent Number 8,063,089. The patent claims allow for a method for treating cancer by administering an effective amount of the product to treat colon, lung, breast, and prostate cancers, or mantle cell lymphoma or acute leukemia.
Nucleophosmin 1 (NPM1), a multifunctional nucleolar phosphoprotein is dysregulated in human malignancies, leading to anti-apoptosis and inhibition of differentiation. "We evaluated the precise three-dimensional structure of NPM 1 based on the highly conserved structure of Xenopus NO38 and its requirement to form dimers and pentamers", stated Daruka Mahadevan M.D., Ph.D., Chief Scientific Officer of TCT, LLC. "Molecular modeling, pharmacophore design, in silico screening and interactive Docking identified NSC348884 as a putative NPM 1 small molecule inhibitor that disrupts a defined hydrophobic pocket required for oligomerization."
Treatment of several different cancer cell types with NSC348884 up-regulated p53 and induced apoptosis in a dose-dependent manner that correlated with apoptotic markers. Further, NSC348884 exquisitely synergizes with doxorubicin on cancer cell viability. The data show that NSC34884 induces apoptosis and synergizes with chemotherapy.
TCT also recently received a U.S. Designation of Patent for its therapeutic CEACAM6 monoclonal antibody targeting pancreatic cancer.
In 2012, 1.6 million new cases of cancer will be diagnosed. It is estimated that greater than half-a-million Americans will die of cancer, which is about 1,500 patients a day. Cancer is the second most com¬mon cause of death in the US, accounting for about 25% of deaths. The 5-year survival for all cancers diagnosed has improved from 49% in the late 1970's to 67% in the 21st century. This improvement in survival is from early diagnosis and modest improvements in treatment. However, the treatment of cancer lags far behind other human diseases. There is a clear unmet need to discover and develop new treatments for most cancers including lymphoma, leukemia and breast, prostate and colon cancer.
For more information on Targeted Cancer Therapeutics LLC and its products,
email info@targetedcancer.com or visit www.targetedcancer.com
About Targeted Cancer Therapeutics (TCT)
Targeted Cancer Therapeutics is a privately held biopharmaceutical company located in California. The company has an exclusive license agreement with the University of Arizona for several products designed for the treatment of cancers. TCT is actively seeking investment capital to further develop its products.
Contact Information
William Mulert, President
(707) 477-7022 bmulert@targetedcancer.com
Nucleophosmin 1 (NPM1), a multifunctional nucleolar phosphoprotein is dysregulated in human malignancies, leading to anti-apoptosis and inhibition of differentiation. "We evaluated the precise three-dimensional structure of NPM 1 based on the highly conserved structure of Xenopus NO38 and its requirement to form dimers and pentamers", stated Daruka Mahadevan M.D., Ph.D., Chief Scientific Officer of TCT, LLC. "Molecular modeling, pharmacophore design, in silico screening and interactive Docking identified NSC348884 as a putative NPM 1 small molecule inhibitor that disrupts a defined hydrophobic pocket required for oligomerization."
Treatment of several different cancer cell types with NSC348884 up-regulated p53 and induced apoptosis in a dose-dependent manner that correlated with apoptotic markers. Further, NSC348884 exquisitely synergizes with doxorubicin on cancer cell viability. The data show that NSC34884 induces apoptosis and synergizes with chemotherapy.
TCT also recently received a U.S. Designation of Patent for its therapeutic CEACAM6 monoclonal antibody targeting pancreatic cancer.
In 2012, 1.6 million new cases of cancer will be diagnosed. It is estimated that greater than half-a-million Americans will die of cancer, which is about 1,500 patients a day. Cancer is the second most com¬mon cause of death in the US, accounting for about 25% of deaths. The 5-year survival for all cancers diagnosed has improved from 49% in the late 1970's to 67% in the 21st century. This improvement in survival is from early diagnosis and modest improvements in treatment. However, the treatment of cancer lags far behind other human diseases. There is a clear unmet need to discover and develop new treatments for most cancers including lymphoma, leukemia and breast, prostate and colon cancer.
For more information on Targeted Cancer Therapeutics LLC and its products,
email info@targetedcancer.com or visit www.targetedcancer.com
About Targeted Cancer Therapeutics (TCT)
Targeted Cancer Therapeutics is a privately held biopharmaceutical company located in California. The company has an exclusive license agreement with the University of Arizona for several products designed for the treatment of cancers. TCT is actively seeking investment capital to further develop its products.
Contact Information
William Mulert, President
(707) 477-7022 bmulert@targetedcancer.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.